Open AccessVariation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment
Author(s) -
Ronald M. Krauss,
Lara M. Mangravite,
Joshua D. Smith,
Marisa W. Medina,
Dai Wang,
Xiuqing Guo,
Mark J. Rieder,
Joel A. Simon,
S B Hulley,
David D. Waters,
Mohammed Saad,
Paul T. Williams,
Kent D. Taylor,
Huiying Yang,
Deborah A. Nickerson,
Jerome I. Rotter
Publication year - 2008
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.107.708388
Subject(s) - medicine , endocrinology , simvastatin , single nucleotide polymorphism , haplotype , reductase , hydroxymethylglutaryl coa reductase , cholesterol , statin , familial hypercholesterolemia , linkage disequilibrium , hmg coa reductase , genetics , allele , enzyme , gene , biology , biochemistry , genotype
Use of 3-hydroxyl-3-methylglutaryl-3 coenzyme A reductase (HMGCR) inhibitors, or statins, reduces cardiovascular disease risk by lowering plasma low-density lipoprotein cholesterol (LDL-C) concentrations. However, LDL-C response is variable and influenced by many factors, including racial ancestry, with attenuated response in blacks compared with whites. We hypothesized that single nucleotide polymorphisms in the gene encoding HMGCR, a rate-limiting enzyme in cholesterol synthesis and the direct enzymatic target of statins, contribute to variation in statin response.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom